Clinical trials: Post-menopausal Women
Post-menopausal Vasomotor Symptoms
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts.
- Trial name
- RELENT-1 (NCT02865538)
- Testing
- BAY3427080
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Bayer
Biological Availability
Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam
Quantify the effect of a probe CYP3A4 inducer (Rifampicin) on the pharmacokinetics of levonorgestrel, norethindrone, desogestrel, dienogest, drospirenone,estradiol and midazolam
- Trial name
- NCT03353857
- Testing
- levonorgestrel/ Microlut, Norethindrone/ Noriday, Desogestrel/ Cerazette
- Where
- 2 sites in Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Bayer
Osteoporosis
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
This is an 18-month, double-blind, placebo-controlled, Phase III trial with a 12-month interim analysis of the effect of ALX1-11, recombinant human parathyroid hormone (1-84) (rhPTH [1-84]), on fracture incidence in women with…
- Trial name
- NCT00172081
- Testing
- ALX1-11
- Where
- 174 sites in United States, Argentina and 7 more
- Volunteers
- 2,532 people
- Sponsor
- Shire
Endometrial Cancer
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
The purpose of the protocol is to determine the effect of BN83495 on the progression of endometrial cancer with estrogen receptor in post menopausal women who had previously received chemotherapy.
- Trial name
- NCT01251354
- Testing
- BN83495
- Where
- 9 sites in United States, Canada
- Volunteers
- 6 people
- Sponsor
- Ipsen
Postmenopausal Osteoporosis
BEATRIS Study: A Study of Adherence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis
This 2 arm study will assess the impact of Bone Marker Feedback (BMF), using blood sampling and communication of the results at 2 months, on adherence to monthly Bonviva (150mg po) in women with post-menopausal osteoporosis.
- Trial name
- NCT00545909
- Testing
- ibandronate [Bonviva/Boniva]
- Where
- 57 sites in Austria, Belgium and 3 more
- Volunteers
- 585 people
- Sponsor
- Hoffmann-La Roche
Post-Menopausal Osteoporosis
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP)…
- Trial name
- NCT03432533
- Testing
- romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
- Where
- 46 sites in United States, Poland and 1 more
- Volunteers
- 283 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
This study will investigate participant satisfaction (including compliance, preference, tolerability) with once-monthly Bonviva in women with post-menopausal osteoporosis or osteopenia transitioned from once-weekly alendronate or…
- Trial name
- NCT02604836
- Testing
- Ibandronate
- Where
- 142 sites in United States
- Volunteers
- 1,711 people
- Sponsor
- Hoffmann-La Roche
Healthy Subjects
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects
The purpose of this study is to evaluate the safety and tolerability of single and multiple oral doses of ESN364 in healthy Japanese male and pre- and post-menopausal female subjects.
- Trial name
- NCT03436849
- Testing
- ESN364
- Where
- Japan
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Postmenopause
Study Assessing the Effects on Endometrium and Breast of Isoflavone in Post Menopausal Women
The main objective of this study is to determine the effects on the endometrium and breast of 70 mg daily dose of isoflavones.
- Trial name
- NCT00235924
- Testing
- soy isoflavone
- Volunteers
- 300 people
- Sponsor
- Laboratoires Arkopharma
Osteoporosis, Postmenopausal
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).
- Trial name
- NCT00383422
- Testing
- Arzoxifene, Raloxifene
- Where
- 21 sites in United States, Argentina and 6 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company
Healthy
Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions
The purpose of this study is to compare bioavailability in healthy, post menopausal women subjects under fasting conditions.
- Trial name
- NCT01155947
- Testing
- Anastrozole
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Postmenopausal Osteoporosis
PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia
The purpose of this study is to evaluate treatment adherence to different regimens of ibandronate in postmenopausal women with osteoporosis or osteopenia who are intolerant to daily or weekly alendronate or risedronate therapy…
- Trial name
- NCT02598453
- Testing
- Ibandronate
- Where
- 60 sites in United States
- Volunteers
- 545 people
- Sponsor
- Hoffmann-La Roche
Advanced Breast Cancer
Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant
The study was designed to identify and register practical observations and experiences in connection with planning and implementing decentralized, patient-centered clinical trials at a geographic distance with virtual elements.
- Trial name
- TELEPIK (NCT04862143)
- Testing
- Alpelisib, Fulvestrant, Goserelin
- Where
- Sweden
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals
Hepatic Impairment
Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects
This will be a Phase I, multicentre, single-dose, non-randomized, open-label, parallel-group study to examine the PK, safety, and tolerability of camizestrant 75 mg in post-menopausal female participants with moderate or severe…
- Trial name
- NCT05790304
- Testing
- Camizestrant
- Where
- 4 sites in United States, Bulgaria and 1 more
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Breast Cancer
Retrospective Observational Trial on Reasons for Withdraw of Adjuvant Tamoxifen in Breast Cancer Patients
Retrospective observational trial on reasons for withdraw of Adjuvant Tamoxifen in Breast Cancer patients
- Trial name
- SOSTA (NCT00727883)
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Breast Cancer
STRIDE - STimulating Immune Response In aDvanced brEast Cancer
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
- Trial name
- STRIDE (NCT00925548)
- Testing
- Tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
- Where
- 29 sites in United States, Australia and 10 more
- Volunteers
- 16 people
- Sponsor
- EMD Serono
Menopause, Hormone Replacement Therapy, Post-Menopausal
Impact of Professional Societies' Recommendations on Practical Use of Hormone Replacement Therapy
This study is conducted in Europe. The aim of this study is to verify the therapeutic effects of low-dose hormone replacement therapy (HRT) in female patients over adequately long time period in normal clinical practice…
- Trial name
- NCT01487304
- Testing
- Marketed low dose hormone replacement therapy
- Where
- Czechia
- Volunteers
- 3,760 people
- Sponsor
- Novo Nordisk A/S
Osteoporosis
Open Label Extension
TRES will evaluate the effects of continued ALX1-11 treatment on the safety and efficacy variables assessed in the OLE study for a maximum treatment duration of 36 months in OLES and TRES combined.
- Trial name
- TRES (NCT00172120)
- Testing
- ALX1-11
- Where
- 12 sites in United States, Argentina
- Volunteers
- 91 people
- Sponsor
- Shire
Vulvovaginal Atrophy
Investigation of Efficacy and Tolerability of a Lactic Acid Containing Vaginal Suppository in Post-menopausal Women With VVA
The aim of the study is to investigate the efficacy and tolerability of a lactic acid containing vaginal suppository with respect to the application in post-menopausal women with VVA.
- Trial name
- NCT04222647
- Testing
- WO533
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Immune System Disorder (Healthy Volunteer)
A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of 500 mg oral BID dose of KD025 in healthy male and post-menopausal female participants.
- Trial name
- NCT05918614
- Testing
- Belumosudil mesylate
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Kadmon, a Sanofi Company